▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

David Haen

XMFHaen

Recent Articles by David Haen

GettyImages-1146913659

Jan 3, 2020 by David Haen

Biotech's Most Volatile Binary Events for Q1

Risk-taking investors flock to biotech for its constant flow of events that can spike or crush the stock prices of the companies developing the latest therapies.

GettyImages-1069755068

Jan 2, 2020 by David Haen

Here's Why Mirum Pharmaceuticals' Stock Jumped in December

This newly public drug developer tripled its stock price in November following positive FDA news.

GettyImages-187921657

Dec 31, 2019 by David Haen

Should You Own These 3 Healthcare Distributors?

These medication movers touch most of the prescriptions in the U.S. Are their stocks a buy?

GettyImages-1146913659

Dec 28, 2019 by David Haen

A $20 Billion Sweet Spot in Biotech

Few biotech companies ever reach that valuation, and if they do, you should snap them up for your portfolio.

GettyImages-1134798607

Dec 23, 2019 by David Haen

These Were the 10 Best Healthcare Stocks of 2019

Helping people stricken with illness can be richly rewarding in more ways than one.

GettyImages-1035982466

Dec 20, 2019 by David Haen

Will Karyopharm’s Stock Take Off in 2020?

Early next year, Karyopharm expects to unveil pivotal clinical trial results that could send shares soaring.

GettyImages-1044578580

Dec 19, 2019 by David Haen

Is Main Street Capital a Great Dividend Stock?

This cash-generating small-business lender has maintained or increased its dividend since going public in 2007.

GettyImages-1061838140

Dec 19, 2019 by David Haen

4 Healthcare Services Companies to Own for the Future

Many investors aren’t aware of the vital roles contract research organizations fulfill for pharmaceutical and biotech companies -- or of the billions they make each year for their services.

GettyImages-1055976022

Dec 18, 2019 by David Haen

Exact Sciences Should Benefit from Pfizer’s News Today

Pfizer announced an expedited FDA review for its drug to treat colorectal cancer, which Exact Sciences’ lead diagnostic test also targets.

GettyImages-1140779754

Dec 14, 2019 by David Haen

Is Codexis Stock a Buy?

This favorite of institutional shareholders remains off the radars of most retail investors.

GettyImages-975236218

Jan 15, 2020 by David Haen

4 Healthcare Stocks With FDA Approvals on the Horizon

With FDA approval deadlines approaching in 2020, these four drug developers could see substantial gains if they're successful.

GettyImages-1063275556

Dec 11, 2019 by David Haen

Is Rigel Pharmaceuticals Stock a Buy?

The real question is whether growing product sales can outpace increasing R&D expenses.

GettyImages-1035988708

Dec 9, 2019 by David Haen

If You Invested $10,000 in Guardant Health's IPO, This Is How Much Money You'd Have Now

This leading diagnostic company's stock has nearly quadrupled in value in just over one year.

GettyImages-670645300

Dec 7, 2019 by David Haen

3 Biotechs Facing FDA Approvals by Year's End

This is your last chance to buy these companies' stocks before the Food and Drug Administration weighs in on the fates of their key candidate treatments.

GettyImages-1165195324

Dec 7, 2019 by David Haen

Biotech’s Year-End To-Do List

The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.

GettyImages-844627708

Dec 6, 2019 by David Haen

2 Breast Cancer Fighting Stocks to Invest In

Promising new results in breast cancer will be presented at next week's San Antonio Breast Cancer Symposium. Here's what to look for.

GettyImages-1033774292

Dec 6, 2019 by David Haen

Save Yourself the Migraine and Buy This 1 Pharma Stock Now

Late-stage clinical trial results provide a chance for investors to gain significant upside from this developer of drugs combating neurological diseases.

GettyImages-691562550

Nov 26, 2019 by David Haen

Better Buy: Editas Medicine or Sangamo Therapeutics?

These gene-editing trailblazers continue advancing exciting new approaches to treating inherited diseases.

GettyImages-522471947

Nov 25, 2019 by David Haen

2 Small-Cap Biotechs That Soared Last Week

New drugs from these companies seek to enable more patients to receive cutting-edge cell and gene therapies.

GettyImages-1097423866

Nov 23, 2019 by David Haen

Global Blood Therapeutics Goes Head to Head With Novartis On Sickle Cell

Transformative new therapies are changing the treatment landscape for patients with sickle cell disease, and savvy investors can benefit in this David-versus-Goliath scenario. Which one is the better buy today?

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services